ABBV
RGNX
The data dump investors wanted
REGENXBIO spent the weekend showing off long-term trial results for surabgene lomparvovec, its gene therapy for wet AMD and diabetic retinopathy. In the wet AMD studies, vision gains held up — or even improved — over five years, while patients needed far fewer anti-VEGF shots than the real-world control groups.
The good news came with a biotech-sized asterisk
The cleanest part of the story? No new safety issues or intraocular inflammation in the study completers. That matters a lot here, because eye therapies live and die on the balance between "works" and "please don’t blind anyone." So far, this one looks sturdier than a lot of speculative gene therapy bets.
AbbVie is still in the room
This isn’t just a REGENXBIO solo act. AbbVie is tied to the ABBV-RGX-314 program, and the two companies are still aiming to drop topline results from the pivotal ATMOSPHERE and ASCENT trials in late 2026. If those readouts land well, this could go from promising science project to actual commercial story.
Oh, and the company also raised cash
Because no biotech update is complete without a financing twist, REGENXBIO also priced a public offering that should bring in about $100 million gross. That’s useful fuel for the runway, but it also means existing shareholders get to enjoy the classic biotech combo plate: encouraging data, plus dilution.
Big picture: the clinical package is getting more convincing, but the stock still has to survive the usual biotech reality check — execution, timing, and whether the market believes the next readout is the one that counts.